Kymera Therapeutics's market cap is currently $2.42B. The company's EPS TTM is $-2.328; its P/E ratio is ―; Kymera Therapeutics is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is $-0.70. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 78.59M	$ 46.83M	$ 72.83M	$ 34.03M	$ 2.93M
Gross Profit	$ -110.49M	$ 43.85M	$ 70.44M	$ -28.07M	$ 2.11M
Operating Income	$ -165.53M	$ -161.26M	$ -100.53M	$ -46.30M	$ -42.20M
EBITDA	$ -143.20M	$ -151.66M	$ -97.64M	$ -43.72M	$ -40.38M
Net Income	$ -146.96M	$ -151.83M	$ -98.00M	$ -43.95M	$ -41.29M
Balance Sheet
Cash & Short-Term Investments	$ 374.88M	$ 559.49M	$ 567.61M	$ 458.73M	$ 91.96M
Total Assets	$ 575.76M	$ 603.13M	$ 605.90M	$ 487.18M	$ 116.70M
Total Debt	$ 84.67M	$ 17.34M	$ 17.96M	$ 17.99M	$ 21.19M
Net Debt	$ -25.29M	$ -51.06M	$ -30.01M	$ -13.01M	$ -54.82M
Total Liabilities	$ 180.79M	$ 112.98M	$ 146.27M	$ 203.29M	$ 191.11M
Stockholders' Equity	$ 394.97M	$ 490.15M	$ 459.64M	$ 283.89M	$ -74.41M
Cash Flow
Free Cash Flow	$ -137.31M	$ -155.92M	$ -130.54M	$ 79.03M	$ 17.37M
Operating Cash Flow	$ -102.83M	$ -153.09M	$ -128.95M	$ 88.13M	$ 17.91M
Investing Cash Flow	$ 139.89M	$ 20.52M	$ -99.83M	$ -422.59M	$ -16.49M
Financing Cash Flow	$ 4.19M	$ 153.00M	$ 250.28M	$ 289.26M	$ 34.91M

Currency in USD

Kymera Therapeutics Earnings and Revenue History

Income Statement >

Kymera Therapeutics Debt to Assets

Balance Sheet >

Kymera Therapeutics Cash Flow

Cash Flow >

Kymera Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing